What Happened? Shares of scientific consulting firm Exponent (NASDAQ:EXPO) jumped 2.3% in the morning session after JPMorgan ...
Schlenker provided guidance: "For the third quarter 2025, as compared to 1 year prior, we expect revenues before reimbursements to be up in the middle single digits and EBITDA to be 26.75% to 27.75% ...
Exponent's Q4 2024 earnings and revenue exceeded forecasts. Stock price increased by 3.54% in after-hours trading. Full-year 2024 revenues grew by 4% to $558.5 million. The company reported a 28.4% ...
Exponent, Inc. (Nasdaq: EXPO), today announced that it will report Fourth Quarter and fiscal year 2025 financial results for the period ended January 2, 2026 following the close of the market on ...